STAMARiL is a live, attenuated vaccine indicated for active immunisation against yellow fever.
STAMARiL Prescribing information
Yellow fever is a potentially fatal viral infection spread between monkeys and humans via the bite from an infected mosquito.1,2 It is found in tropical parts of Central and South America and sub-Saharan Africa.2
STAMARiL provides at least 10 years’ protection against yellow fever from around 10 days after vaccination - the duration of protection may be lifelong.
|
|
Presentation |
Schedule |
Further doses |
Age range |
|
|
0.5 ml prefilled diluent |
1 dose |
The duration of protection following administration of one dose of Stamaril® is expected to be at least 10 years and may be life-long. Re-vaccination may be needed in some individuals who had an insufficient immune response after their primary vaccination. Re-vaccination may also be required, depending on official recommendations of local Health Authorities, as a condition of entry in some countries |
9 months + For information about administration in children from 6 to 9 months of age, and in persons over 60 years of age, please refer to the SmPC |
References:
Before you prescribe this vaccine please refer to the Prescribing information and SmPC links below.
Sanofi Pasteur is committed to providing you and your patients with a comprehensive range of support materials, including disease awareness patient leaflets and in-surgery display items.
• Simply visit https://sanofi.medisa.com
• Select the user group which best describes your role in your organisation
• Narrow your search by selecting the appropriate disease area
• Select which materials you would like to receive and how many
• Log-in or register to create an account
• Confirm your order
Date of preparation: November 2018 | SAGB.MIS.18.08.1323v
